Myeloid-Lymphoid Leukemia Protein
"Myeloid-Lymphoid Leukemia Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
| Descriptor ID |
D051788
|
| MeSH Number(s) |
D12.776.260.560 D12.776.624.664.700.148 D12.776.930.483
|
| Concept/Terms |
Myeloid-Lymphoid Leukemia Protein- Myeloid-Lymphoid Leukemia Protein
- Myeloid Lymphoid Leukemia Protein
- Zinc Finger Protein HRX
- MLL Proto-Oncogene Protein
- MLL Proto Oncogene Protein
- Proto-Oncogene Protein, MLL
- Proto-Oncogene Proteins MLL
- MLL, Proto-Oncogene Proteins
- Proto Oncogene Proteins MLL
- Acute Lymphoblastic Leukemia Protein 1
- Mixed-Lineage Leukemia Protein
- Mixed Lineage Leukemia Protein
|
Below are MeSH descriptors whose meaning is more general than "Myeloid-Lymphoid Leukemia Protein".
Below are MeSH descriptors whose meaning is more specific than "Myeloid-Lymphoid Leukemia Protein".
This graph shows the total number of publications written about "Myeloid-Lymphoid Leukemia Protein" by people in this website by year, and whether "Myeloid-Lymphoid Leukemia Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2010 | 3 | 0 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 4 | 1 | 5 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 2 | 6 |
| 2024 | 3 | 3 | 6 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid-Lymphoid Leukemia Protein" by people in Profiles.
-
Synthesis, Structure-Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein-Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. J Med Chem. 2025 Sep 25; 68(18):19396-19414.
-
The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes. Arch Pathol Lab Med. 2025 Aug 01; 149(8):717-726.
-
Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. Nat Commun. 2025 Mar 18; 16(1):2641.
-
MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024 10 29; 15(1):9341.
-
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol. 2024 Oct 04; 7(1):1257.
-
The epigenetic state of the cell of origin defines mechanisms of leukemogenesis. Leukemia. 2025 Jan; 39(1):87-97.
-
Identification of single-cell blasts in pediatric acute myeloid leukemia using an autoencoder. Life Sci Alliance. 2024 Nov; 7(11).
-
Histone H3K18 & H3K23 acetylation directs establishment of MLL-mediated H3K4 methylation. J Biol Chem. 2024 08; 300(8):107527.
-
Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia. Pediatr Blood Cancer. 2024 Jun; 71(6):e30964.
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 01 01; 109(1):293-297.